LexBio and Hiteck partner to develop novel drug candidates using AI-driven molecular glue degraders targeting B- and T-cell pathways for immune-related diseases.

2025 CPHI China Pharmaceutical R&D Cloud Summit.Dr. Li Xing was invited to give a talk of“AI-Powered  Efficient Discovery of Clinical Candidates”.

LexBio was awarded the prestigious title of “Honored Enterprise”at the 2025 NVIDIA INCEPTION SHOWCASE, recognized for its groundbreaking innovation and advanced capabilities in AI-driven drug discove.

Dr. Li Xing was invited to deliver a presentation titled "AI accelerated drug discovery" at the DSSM&TPD 2025 conference.

2025 CBA-China Annual Conference.Dr. Li Xing was invited to give a talk of“Al accelerated antibody discovery”.

2024 RESI J.P. Morgan was successfully held on 26-28 Feb. 2024 in San Francisco, US. Dr. Li Xing was invited as a special guest to participate as Entrepreneur's Workshop of this conferences.

2024 ESMO TAT Congress was held in Paris, France, on Feb 26-28, 2024. Dr. Li Xing was invited to present "HIGHLY POTENT AND SELECTIVE RET INHIBITORS THAT OVERCOME ADAPTIVE DRUG RESISTANCE".

Dr. Li Xing was invited as a special guest to host and share profound insights on "In-depth Exploration of AI Applications in the field of Life Sciences" in the 2024 BIO CHINA Live Webcast.

Dr. Xing advanced drug discovery projects through stage gate transitions,  supervised post-doctoral research, built the AI technology unit and led it to profit.

How significant is the role of artificial intelligence in new drug development at this stage? Let's hear what the experts say.

PharmCube Pro interviewed Dr. Xing Li, the CEO of LexBio, at the 7th Annual Meeting of the Biotech Founders Club.

LexBio was awarded the Winner's Prize at 'Jiangsu Innovation and Entrepreneurship' competition. It featured six industry categories, and sixty teams and companies advanced to the final round.

Dr. Xing Li, CEO of LexBio, was invited to join the BiG & Bohe Live Broadcast "Pioneering Progress! AI in Small Molecule Drug Discovery"

LexBio was selected as one of the six programs to present at the 'Jiangsu Innovation and Entrepreneurship' Special Roadshow event.

After rounds of competitions the winners were selected to advance to the National Finals.

Shanghai Medicilon (SHA: 688202) and LexBio signed an agreement to collaborate on innovative pharmaceutical research and development through the application of LexBio's AI platform.

In today's special interview with a technology leader, we walk into LexBio and hear from Dr. Xing Li, the founder and CEO of the company, as she shares her entrepreneurial journey.

Tens of thousands of projects were showcased at the 10th Competition. After several rounds of intense competition Pingke Microelectronics won championship and LexBio won runner up.